Vaxcyte Inc
For the period ended Dec 31, 2024. Filed Feb 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 25, 2025
PCVX$67.53+5.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
Exhibit Index
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| Exhibit | Description | Form | File Number | Exhibit | Filing Date |
| 3.1 | Amended and Restated Certificate of Incorporation of Vaxcyte, Inc., as amended | 8-K | 001-39323 | 3.1 | June 16, 2020 |
| 3.2 | Amended and Restated Bylaws of Vaxcyte, Inc., as amended. | 10-Q | 001-39323 | 3.2 | November 6, 2023 |
| 4.1 | Form of Common Stock Certificate of the Registrant. | S-1/A | 333-238630 | 4.1 | June 8, 2020 |
| 4.2 | Description of Capital Stock. | 10-K | 001-39323 | 4.2 | March 29, 2021 |
| 4.3 | Form of Pre-Funded Warrant. | 8-K | 001-39323 | 4.1 | January 13, 2022 |
| 4.4 | Form of Pre-Funded Warrant. | 8-K | 001-39323 | 4.1 | October 27, 2022 |
| 4.5 | Form of Pre-Funded Warrant. | 8-K | 001-39323 | 4.1 | April 20, 2023 |
| 4.6 | Form of Pre-Funded Warrant. | 8-K | 001-39323 | 4.1 | January 31, 2024 |
| 4.7 | Form of Pre-Funded Warrant. | 8-K | 001-39323 | 4.1 | September 6, 2024 |
| 10.1# | Vaxcyte, Inc. Amended and Restated 2014 Equity Incentive Plan and forms of agreements thereunder. | S-1 | 333-238630 | 10.2 | May 22, 2020 |
| 10.2# | Vaxcyte, Inc. 2020 Equity Incentive Plan. | 10-Q | 001-39323 | 10.1 | August 8, 2023 |
| 10.3# | Form of Stock Option Grant Notice and Stock Option Agreement (2020 Equity Incentive Plan). | 10-Q | 001-39323 | 10.2 | August 8, 2023 |
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| Exhibit | Description | Form | File Number | Exhibit | Filing Date |
| 10.4# | Form of Restricted Stock Unit Grant Notice (2020 Equity Incentive Plan). | 10-Q | 001-39323 | 10.2 | May 9, 2022 |
| 10.5# | Vaxcyte, Inc. 2020 Employee Stock Purchase Plan. | S-1/A | 333-238630 | 10.4 | June 8, 2020 |
| 10.6 | Form of Indemnification Agreement entered into by and between the Registrant and each director and executive officer. | S-1 | 333-238630 | 10.5 | May 22, 2020 |
| 10.7# | Executive Employment Agreement entered into by and between the Registrant and Grant Pickering, dated January 21, 2016. | S-1 | 333-238630 | 10.6 | May 22, 2020 |
| 10.8# | Executive Employment Agreement entered into by and between the Registrant and Jim Wassil, dated November 15, 2019. | S-1 | 333-238630 | 10.11 | May 22, 2020 |
| 10.9# | Offer Letter entered into by and between the Registrant and Andrew Guggenhime, dated April 16, 2020. | S-1 | 333-238630 | 10.13 | May 22, 2020 |
| 10.10# | Offer Letter entered into by and between the Registrant and Mikhail Eydelman, dated March 4, 2022. | 10-Q | 001-39323 | 10.1 | May 9, 2022 |
| 10.11# | Form of Executive Change in Control and Severance Agreement entered into by and between the Registrant and each eligible employee. | S-1 | 333-238630 | 10.14 | May 22, 2020 |
| 10.12+† | Master Services Agreement for Drug Product Development and Manufacturing between Registrant and Lonza Ltd., dated March 22, 2022, as amended. | 10-K | 001-39323 | 10.12 | February 27, 2024 |
| 10.13+† | Development and Manufacturing Services Agreement by and between the Registrant and Lonza Ltd., dated March 1, 2023. | 10-Q | 001-39323 | 10.1 | May 8, 2023 |
| 10.14+† | Commercial Manufacturing and Supply Agreement by and between the Registrant and Lonza Ltd., dated October 13, 2023. | 10-K | 001-39323 | 10.14 | February 27, 2024 |
| 10.15+† | Amended and Restated SutroVax Agreement by and between the Registrant and Sutro Biopharma, Inc., dated October 12, 2015, as amended. | S-1 | 333-238630 | 10.18 | May 22, 2020 |
| 10.16+† | Third Amendment to Amended and Restated SutroVax Agreement by and between Sutro Biopharma, Inc. and the Registrant, dated September 28, 2023. | 10-Q | 001-39323 | 10.3 | November 6, 2023 |
| 10.17+† | Supply Agreement by and between the Registrant and Sutro Biopharma, Inc., dated May 29, 2018, as amended. | 10-K | 001-39323 | 10.19 | February 27, 2023 |
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| Exhibit | Description | Form | File Number | Exhibit | Filing Date |
| 10.18+† | Option Grant Agreement by and between Registrant and Sutro Biopharma, Inc., dated December 19, 2022. | 10-K | 001-39323 | 10.20 | February 27, 2023 |
| 10.19+† | Manufacturing Rights Agreement by and between the Registrant and Sutro Biopharma, Inc., dated November 21, 2023. | 10-K | 001-39323 | 10.19 | February 27, 2024 |
| 10.20+† | License Agreement by and between the Registrant and The Regents of the University of California, represented by its San Diego campus, dated February 4, 2019. | S-1 | 333-238630 | 10.20 | May 22, 2020 |
| 10.21 | First Amendment to License Agreement by and between the Registrant and The Regents of the University of California, represented by its San Diego campus, dated August 16, 2019. | 10-K | 001-39323 | 10.21 | February 27, 2024 |
| 10.22+† | Amended and Restated Lease Agreement by and between the Registrant and ARE-San Francisco No. 63, LLC, dated as of November 15, 2024 | X | |||
| 10.23# | Form of Non-U.S. Stock Option Grant Notice and Stock Option Agreement (2020 Equity Incentive Plan). | 10-K | 001-39323 | 10.26 | February 27, 2024 |
| 10.24# | Form of Non. U.S. Restricted Stock Unit Grant Notice (2020 Equity Incentive Plan). | 10-K | 001-39323 | 10.27 | February 27, 2024 |
| 19.1 | Vaxcyte, Inc. Insider Trading Policy | X | |||
| 21.1 | Subsidiary of Registrant. | 10-K | 001-39323 | 21.1 | February 27, 2024 |
| 23.1 | Consent of Independent Registered Public Accounting Firm. | X | |||
| 24.1 | Power of Attorney. Reference is made to the signature page hereto. | X | |||
| 31.1 | Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended. | X | |||
| 31.2 | Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended. | X | |||
| 32.1* | Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 13a-14(b) or 15d-14(b) of the Securities Exchange Act, as amended, and 18 U.S.C. Section 1350. | X | |||
| 97.1# | Incentive Compensation Recoupment Policy. | 10-K | 001-39323 | 97.1 | February 27, 2024 |
| Incorporated by Reference | |||||
| Exhibit | Description | Form | File Number | Exhibit | Filing Date |
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. | X | |||
| 101.SCH | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents. | X | |||
| 104 | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101). | X | |||
X Filed herewith.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.